title: Efficacy and tolerability of an argentine intravenous immunoglobulin in pediatric patients with primary immunodeficiency diseases.
abstract: Inmunoglobulina G Endovenosa UNC is a 5% liquid Argentine intravenous immunoglobulin obtained from South American donors. This prospective trial was designed to evaluate if the product meets the minimal efficacy requirement of the US Food and Drug Administration of <1 serious infection/subject/year as well as its safety in pediatric patients with Primary Immunodeficiency Diseases. Thirty patients under the age of 18, with well-defined Primary Immunodeficiency Diseases received Inmunoglobulina G Endovenosa UNC (330-700 mg/kg every 3-4 weeks) for 6 months. Vital signs, laboratory abnormalities, adverse events and viral tests were assessed to evaluate safety. Two serious infections occurred (pneumonia and bacteriemia). The estimated infection rate was 0.114 serious infection/subject/year (95% CI, 0.003-0.2277). Minor adverse events occurred in 5.5% of infusions; fever and headache were the most common. Neither severe adverse events, nor abnormal laboratory values were observed. All viral assessments were negative. Inmunoglobulina G Endovenosa UNC meets the minimal efficacy requirement of the US Food and Drug Administration for pediatric Primary Immunodeficiency Diseases patients and showed efficacy and safety data comparable with other data published.
authors.affiliation: Immunology Unit, Hospital de Pediatría "Prof. Dr. J. P. Garrahan", Combate de los Pozos 1881, Buenos Aires, (C 1245 AAM), Argentina.
authors.forename: S
authors.initials: S
authors.lastname: Krasovec
authors.forename: A
authors.initials: A
authors.lastname: Ornani
authors.forename: M
authors.initials: M
authors.lastname: Oleastro
authors.forename: S
authors.initials: S
authors.lastname: Rosenzweig
authors.forename: A
authors.initials: A
authors.lastname: Roy
authors.forename: L
authors.initials: L
authors.lastname: Perez
authors.forename: G
authors.initials: G
authors.lastname: Campos
authors.forename: N
authors.initials: N
authors.lastname: Marín
authors.forename: A
authors.initials: A
authors.lastname: Martinez
authors.forename: C
authors.initials: C
authors.lastname: Mahieu
authors.forename: M J
authors.initials: MJ
authors.lastname: Manfredi
authors.forename: A
authors.initials: A
authors.lastname: Sisti
authors.forename: M
authors.initials: M
authors.lastname: Zelazko
mesh_terms: D000293:Adolescent; D001118:Argentina; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007239:Infections / Q000453:epidemiology; D008297:Male; D016896:Treatment Outcome
chemical_list: D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous